{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:38Z","timestamp":1791449438578,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01890-z","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:56:51Z","timestamp":1789181811000},"page":"5133-5148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1337-3836","authenticated-orcid":false,"given":"David L.","family":"Ranzinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schmidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Wasserer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Technau-Hafsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Has","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-4556","authenticated-orcid":false,"given":"Anna C.","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"1890_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2165\/00128071-200304020-00003","volume":"4","author":"SM Cooper","year":"2003","unstructured":"Cooper SM, Burge SM. Darier\u2019s disease: epidemiology, pathophysiology, and management. Am J Clin Dermatol. 2003;4:97\u2013105. https:\/\/doi.org\/10.2165\/00128071-200304020-00003.","journal-title":"Am J Clin Dermatol"},{"key":"1890_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/1203475421999331","volume":"25","author":"A Yeshurun","year":"2021","unstructured":"Yeshurun A, Ziv M, Cohen-Barak E, Vered S, Rozenman D, Sah M, et\u00a0al. An update on the cutaneous manifestations of Darier disease. J Cutan Med Surg. 2021;25:498\u2013503. https:\/\/doi.org\/10.1177\/1203475421999331.","journal-title":"J Cutan Med Surg"},{"key":"1890_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/0190-9622(92)70154-8","volume":"27","author":"SM Burge","year":"1992","unstructured":"Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol. 1992;27:40\u201350. https:\/\/doi.org\/10.1016\/0190-9622(92)70154-8.","journal-title":"J Am Acad Dermatol"},{"key":"1890_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/jdv.20448","volume":"39","author":"M Ettinger","year":"2025","unstructured":"Ettinger M, Kimeswenger S, Deli I, Traxler J, Altrichter S, Noack P, et\u00a0al. Darier disease: current insights and challenges in pathogenesis and management. J Eur Acad Dermatol Venereol. 2025;39:942\u201351. https:\/\/doi.org\/10.1111\/jdv.20448.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1890_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70483","author":"S Labbouz","year":"2026","unstructured":"Labbouz S, Hovnanian A, Xiong G, Murrell DF, Mueller SM, Ezzedine K, et\u00a0al. Darier disease\u2014a review highlighting new insights from the Darier Disease International Task Force. J Eur Acad Dermatol Venereol. 2026. https:\/\/doi.org\/10.1111\/jdv.70483.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1890_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-023-01587-x","volume":"11","author":"Y Amar","year":"2023","unstructured":"Amar Y, Rogner D, Silva RL, Foesel BU, Ud-Dean M, Lagkouvardos I, et\u00a0al. Darier\u2019s disease exhibits a unique cutaneous microbial dysbiosis associated with inflammation and body malodour. Microbiome. 2023;11:162. https:\/\/doi.org\/10.1186\/s40168-023-01587-x.","journal-title":"Microbiome"},{"key":"1890_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/ddg.12899","volume":"14","author":"M Geroldinger-Simic","year":"2016","unstructured":"Geroldinger-Simic M, Jabkowski J, Klein G. Generalized herpes simplex virus infection in Darier\u2019s disease. J Dtsch Dermatol Ges. 2016;14:841\u20132. https:\/\/doi.org\/10.1111\/ddg.12899.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1890_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8133","volume":"12","author":"P Ashok Kumar","year":"2020","unstructured":"Ashok Kumar P, Paulraj S, Dutta S. Debilitating Darier\u2019s disease and its impact on the quality of life. Cureus. 2020;12:e8133. https:\/\/doi.org\/10.7759\/cureus.8133.","journal-title":"Cureus"},{"key":"1890_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1365-2133.2010.09834.x","volume":"163","author":"K Gordon-Smith","year":"2010","unstructured":"Gordon-Smith K, Jones LA, Burge SM, Munro CS, Tavadia S, Craddock N. The neuropsychiatric phenotype in Darier disease. Br J Dermatol. 2010;163:515\u201322. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09834.x.","journal-title":"Br J Dermatol"},{"key":"1890_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63832-9","volume":"10","author":"E Bachar-Wikstrom","year":"2020","unstructured":"Bachar-Wikstrom E, Curman P, Ahanian T, Leong IUS, Larsson H, Cederl\u00f6f M, et\u00a0al. Darier disease is associated with heart failure: a cross-sectional case\u2013control and population based study. Sci Rep. 2020;10:6886. https:\/\/doi.org\/10.1038\/s41598-020-63832-9.","journal-title":"Sci Rep"},{"key":"1890_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jaad.2019.05.087","volume":"81","author":"M Cederl\u00f6f","year":"2019","unstructured":"Cederl\u00f6f M, Curman P, Ahanian T, Leong IUS, Brismar K, Bachar-Wikstrom E, et\u00a0al. Darier disease is associated with type 1 diabetes: findings from a population-based cohort study. J Am Acad Dermatol. 2019;81:1425\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2019.05.087.","journal-title":"J Am Acad Dermatol"},{"key":"1890_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/6784","volume":"21","author":"A Sakuntabhai","year":"1999","unstructured":"Sakuntabhai A, Ruiz-Perez V, Carter S, Jacobsen N, Burge S, Monk S, et\u00a0al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet. 1999;21:271\u20137. https:\/\/doi.org\/10.1038\/6784.","journal-title":"Nat Genet"},{"key":"1890_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/antib13030076","volume":"13","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Verduci C, Laconi E, Mangione A, Dondi C, Del Vecchio M, et\u00a0al. Therapeutic advances in psoriasis: from biologics to emerging oral small molecules. Antibodies (Basel). 2024;13:76. https:\/\/doi.org\/10.3390\/antib13030076.","journal-title":"Antibodies (Basel)."},{"key":"1890_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/all.70061","volume":"81","author":"MS de Bruin-Weller","year":"2026","unstructured":"de Bruin-Weller MS, Boesjes CM, Achten RA, Beck LA, Irvine AD, Vestergaard C, et\u00a0al. Biologics to treat atopic dermatitis: effectiveness, safety, and future directions. Allergy. 2026;81:326\u201344. https:\/\/doi.org\/10.1111\/all.70061.","journal-title":"Allergy"},{"key":"1890_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/bjd\/ljae420","volume":"192","author":"J Mazereeuw-Hautier","year":"2025","unstructured":"Mazereeuw-Hautier J, Granier Tournier C, Hernandez-Martin A, Milesi S, Texier H, Severino-Freire M, et\u00a0al. Biologics in congenital ichthyosis: are they effective? Br J Dermatol. 2025;192:327\u201334. https:\/\/doi.org\/10.1093\/bjd\/ljae420.","journal-title":"Br J Dermatol"},{"key":"1890_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jdv.70058","volume":"40","author":"M Ettinger","year":"2026","unstructured":"Ettinger M, Burner T, Lackner A, Deli I, Traxler J, Altrichter S, et\u00a0al. Personalized biologic treatments for patients with Darier disease result in varying responses. J Eur Acad Dermatol Venereol. 2026;40:513\u20136. https:\/\/doi.org\/10.1111\/jdv.70058.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1890_CR17","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamadermatol.2024.2298","volume":"160","author":"H BinJadeed","year":"2024","unstructured":"BinJadeed H, Huang HZ, Joly-Chevrier M, Javed G, Netchiporouk E. Favorable response to type 2 inhibitors in patients with Darier disease. JAMA Dermatol. 2024;160:1007\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2298.","journal-title":"JAMA Dermatol"},{"key":"1890_CR18","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v106.adv-2026-0322","volume":"106","author":"E Burle","year":"2026","unstructured":"Burle E, Mazereeuw-Hautier J, Severino-Freire M. Reconsidering efficacy and safety: a critical appraisal of repurposing anti-inflammatory targeted drugs in Darier disease. Acta Derm Venereol. 2026;106:0322. https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0322.","journal-title":"Acta Derm Venereol"},{"key":"1890_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2025.100381","volume":"5","author":"P Jonsson","year":"2025","unstructured":"Jonsson P, Pilz AC, Maboudi H, Ranzinger D, Wagner P, Schaffert-Stone L-N, et\u00a0al. The translational dermatology initiative: aiming at a new disease classification of inflammatory skin diseases. JID Innov. 2025;5:100381. https:\/\/doi.org\/10.1016\/j.xjidi.2025.100381.","journal-title":"JID Innov"},{"key":"1890_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica. 1978;157:238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"key":"1890_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1890_CR22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, Eckert L, Abb\u00e9 A, Nelson L, et\u00a0al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761\u20139. https:\/\/doi.org\/10.1111\/bjd.17744.","journal-title":"Br J Dermatol"},{"key":"1890_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/jdv.16146","volume":"34","author":"B Schuster","year":"2020","unstructured":"Schuster B, Ziehfreund S, Albrecht H, Spinner CD, Biedermann T, Peifer C, et\u00a0al. Happiness in dermatology: a holistic evaluation of the mental burden of skin diseases. J Eur Acad Dermatol Venereol. 2020;34:1331\u20139. https:\/\/doi.org\/10.1111\/jdv.16146.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1890_CR24","volume-title":"ESS Round 8 Source Questionnaire","author":"European Social Survey","year":"2016","unstructured":"European Social Survey. ESS Round 8 Source Questionnaire. London: ESS ERIC Headquarters c\/o City University London; 2016."},{"key":"1890_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamadermatol.2023.4481","volume":"160","author":"A Shields","year":"2024","unstructured":"Shields A, Armstrong AW, Kaur MN, Layton A, Thiboutot D, Tan J, et\u00a0al. Evaluation of DermSat-7 for assessing treatment satisfaction in patients with acne. JAMA Dermatol. 2024;160:88\u201392. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4481.","journal-title":"JAMA Dermatol"},{"key":"1890_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1159\/000518966","volume":"238","author":"AH Kohn","year":"2021","unstructured":"Kohn AH, Alavi A, Armstrong AW, Babalola F, Garg A, Gottlieb AB, et\u00a0al. International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology. 2021;238:430\u20137. https:\/\/doi.org\/10.1159\/000518966.","journal-title":"Dermatology"},{"key":"1890_CR27","doi-asserted-by":"publisher","unstructured":"Haber RN, Dib NG. Management of Darier disease: a review of the literature and update. Indian J Dermatol Venereol Leprol. 2021;87:14\u201321. https:\/\/doi.org\/10.25259\/IJDVL_963_19","DOI":"10.25259\/IJDVL_963_19"},{"key":"1890_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract15030048","volume":"15","author":"LG Popa","year":"2025","unstructured":"Popa LG, Giurcaneanu C, Zaharia F, Grigoras A, Oprea AD, Beiu C. Dupilumab, a potential novel treatment for Hailey-Hailey disease. Clin Pract (Lond). 2025;15:48. https:\/\/doi.org\/10.3390\/clinpract15030048.","journal-title":"Clin Pract (Lond)"},{"key":"1890_CR29","doi-asserted-by":"publisher","unstructured":"Debeuf M-EPH, Vlaanderen P, van Geel M, Steijlen PM, Verstraeten VLRM. Dupilumab for Hailey\u2013Hailey disease. J Dermatolog Treat. 2025;36:2557477. https:\/\/doi.org\/10.1080\/09546634.2025.2557477","DOI":"10.1080\/09546634.2025.2557477"},{"key":"1890_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jdcr.2024.09.030","volume":"55","author":"D Patel","year":"2025","unstructured":"Patel D, Rosenberg J, Cohen J, Holland KE. Effective treatment of recalcitrant Hailey-Hailey disease with dupilumab. JAAD Case Rep. 2025;55:105\u201310. https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.030.","journal-title":"JAAD Case Rep"},{"key":"1890_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ced\/llae507","volume":"50","author":"A Simon Gozalbo","year":"2025","unstructured":"Simon Gozalbo A, Mauleon Fernandez C, Carrascosa de Lome R, Martin Diaz MA, de la Cueva Dobao P. Refractory benign familial pemphigus successfully treated with dupilumab: a case series. Clin Exp Dermatol. 2025;50:841\u20134. https:\/\/doi.org\/10.1093\/ced\/llae507.","journal-title":"Clin Exp Dermatol"},{"key":"1890_CR32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86817","volume":"17","author":"J Breimann","year":"2025","unstructured":"Breimann J, Agarwala SN, Waseh S, Hsu S. Successful treatment of Hailey-Hailey disease with dupilumab. Cureus. 2025;17:e86817. https:\/\/doi.org\/10.7759\/cureus.86817.","journal-title":"Cureus"},{"key":"1890_CR33","first-page":"18","volume":"18","author":"C Sulich-Moore","year":"2025","unstructured":"Sulich-Moore C, Altman D, Gildenberg S. Treatment of recalcitrant Hailey\u2013Hailey disease with dupilumab: a case report. J Clin Aesthet Dermatol. 2025;18:18\u201320.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1890_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.70023x","author":"O Brandt","year":"2026","unstructured":"Brandt O, Huber SM, Mueller SM. Rapid and long-lasting remission of refractory Hailey-Hailey disease by IL-13 inhibition with tralokinumab. JDDG J Dtsch Dermatol Ges. 2026. https:\/\/doi.org\/10.1111\/ddg.70023x.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1890_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jdcr.2024.07.008","volume":"52","author":"KS Garg","year":"2024","unstructured":"Garg KS, Silverberg J, Tjahjono L. Hailey-Hailey disease successfully treated with tralokinumab and literature review of successful treatment with dupilumab. JAAD Case Rep. 2024;52:18\u201320. https:\/\/doi.org\/10.1016\/j.jdcr.2024.07.008.","journal-title":"JAAD Case Rep"},{"key":"1890_CR36","unstructured":"Adusumilli N, Tjahjono L, Friedman A. IL-13 Blockade for benign familial pemphigus. Dermatology Times. MJH Life Sciences; 2026;47. https:\/\/www.dermatologytimes.com\/view\/il-13-blockade-for-benign-familial-pemphigus. Accessed 24 May 2026"},{"key":"1890_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2026.01.006","author":"H Mummareddy","year":"2026","unstructured":"Mummareddy H, Adusumilli NC, Friedman AJ, Tolete C, Zahn J, Tjahjono L. Benign familial pemphigus treated with lebrikizumab. JAAD Case Rep. 2026. https:\/\/doi.org\/10.1016\/j.jdcr.2026.01.006.","journal-title":"JAAD Case Rep"},{"key":"1890_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.168955","volume":"8","author":"QR Roth-Carter","year":"2023","unstructured":"Roth-Carter QR, Burks HE, Ren Z, Koetsier JL, Tsoi LC, Harms PW, et\u00a0al. Transcriptional profiling of rare acantholytic disorders suggests common mechanisms of pathogenesis. JCI Insight. 2023;8:e168955. https:\/\/doi.org\/10.1172\/jci.insight.168955.","journal-title":"JCI Insight"},{"key":"1890_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43210-5","volume":"14","author":"M Ettinger","year":"2023","unstructured":"Ettinger M, Burner T, Sharma A, Chang Y-T, Lackner A, Prompsy P, et\u00a0al. Th17-associated cytokines IL-17 and IL-23 in inflamed skin of Darier disease patients as potential therapeutic targets. Nat Commun. 2023;14:7470. https:\/\/doi.org\/10.1038\/s41467-023-43210-5.","journal-title":"Nat Commun"},{"key":"1890_CR40","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/ijd.17751","volume":"64","author":"CM Giorgio","year":"2025","unstructured":"Giorgio CM, Di Brizzi EV, Licata G, Fiorentino C, Argenziano G, Balato A. Brodalumab for Darier disease: a case series highlighting IL-17 inhibition as a potential treatment. Int J Dermatol. 2025;64:1720\u20132. https:\/\/doi.org\/10.1111\/ijd.17751.","journal-title":"Int J Dermatol"},{"key":"1890_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et\u00a0al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385:142\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2102383.","journal-title":"N Engl J Med"},{"key":"1890_CR42","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","volume":"32","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, et\u00a0al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018;32:1940\u20139. https:\/\/doi.org\/10.1111\/jdv.15012.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01890-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01890-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:19Z","timestamp":1791446419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01890-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1890"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01890-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David L. Ranzinger received speaker\u2019s fees and\/or travel grants from Abbvie and UCB. Paul Schmidle has no conflicts of interest to declare. Matthias Seifert and Kristin Technau-Hafsi have nothing to disclose. Sophia Wasserer received speaker\u2019s and\/or travel fees from Janssen-Cilag Pharma, Novartis Pharma, Lilly, Almirall, Abbvie, BMS, and Sanofi. Cristina Has has received fees as an advisor and\/or speaker for Krystal, Chiesi, Leo, Allmiral, and Novartis. Cristina Has is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Cristina Has was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kilian Eyerich is an advisory board member or speaker for Abbvie, Almirall, Boehringer Ingelheim, BMS, Leo, Lilly, Janssen, Galderma, Novartis, Pfizer, Sanofi, and UCB as well as co-founder of Dermagnostix R&D GmbH and Dermagnostix GmbH. Anna C. Pilz received consulting and\/or speaker\u2019s fees and\/or travel grants from Abbvie, ALK\u2010Abell\u00f3, Bristol Myers Squibb, Boehringer Ingelheim, LEO Pharma, Novartis, and UCB.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethical committee of the University of Freiburg (25\u20131202-S1-retro) and was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}